Affinium initiates dosing in Phase 1 IV clinical trial of antibiotic prodrug.

Affinium also announces today the closing of a follow-on funding round with its current traders which works with the continued development of AFN-1720. AFN-1720, the AFN-1252 prodrug, is Affinium's lead substance in a completely new class of antibiotics inhibiting bacterial fatty acid biosynthesis inhibition. AFN-1252 is targeted particularly to Staphylococcus spp, the most common bacterial

Chronic discomfort.

AVANIR Pharmaceuticals receives patent for low-dose quinidine formulations of Zenvia to treat PBA AVANIR Pharmaceuticals, Inc. U.S cialis online pharmacy . Patent #7 7,659,282 titled Pharmaceutical Compositions Comprising Dextromethorphan and Quinidine for the Treatment of Neurological Disorders was released on February 9, 2010. The brand new patent will provide AVANIR with patent protection for low-dosage

Regarding to Doctors at Driscoll Childrens Hospital.

12-year-old cancer victim taken into care after parents block treatment about religious grounds State Child Protective Solutions in Texas are likely to court on June 15 to get custody of a 12-year-old girl suffering from advanced Hodgkin’s disease. Regarding to Doctors at Driscoll Children’s Hospital, Katie Wernecke requirements continued radiation and chemotherapy therapy to take

Insurance and treatments.

In Western practice, in the package, along with permanent total disability, a loss of professional capacity for work is suggested, that is, the loss of the opportunity to engage in any specific professional activity, for example, due to the formation of the insured person. In the US space before, such coverage is devoid of economic

University of Queensland investigating reports of ED research.

– Dr Rodney L . University of Queensland investigating reports of research, whether exercise can slow or reverse age-related decline in neural stem cells and thus slow or prevent age-related cognitive decline. Wednesday, 11.30. Background on the technical approachMany-to clinically relevant interactions by inhibition and / or induction of a CYP enzyme such as

Genes Help Set Menopause Timing: Study: MONDAY.

Genes Help Set Menopause Timing: Study: – MONDAY, Sept. 28, 2015 – – Genetic variations seem to have an impact on the age range when a woman enters both puberty and menopause, researchers report . These findings may lead to ways to help predict the timing of menopause, which marks the end of a

Neurosciences/CNS ed pills.

– Transaction Valued at $66 Billion or $219 per Share in Money and Actavis Shares – – Fastest Growing, Most Dynamic Pharmaceutical Organization in Global Healthcare – – Leading Blockbuster Franchises in Ophthalmology, Neurosciences/CNS, Medical Aesthetics/Dermatology/Plastic Surgery, Women's Health, Gastroenterology and Urology – – Positioned for Long-Term Double-Digit Organic Income and Earnings Growth – –

New evidence reveals.

AIDS might be a major accident of evolution The virulence characteristic of HIV-1 – the virus predominantly in charge of human AIDS – might amount to a major accident of evolution, new evidence reveals. A gene function lost during viral evolution predisposed HIV-1 to spur the fatal disease fighting capability failures that are the hallmarks

Published today [13 Dec] in the Journal of Neuroscience.

Acetylcholine may weaken synaptic connections between neurons in brain Experts from the University of Bristol have discovered that a chemical substance in the brain can weaken the synaptic connections between neurons in a region of the brain important for the forming of long-term memoriesResearchers from the University of Bristol have discovered that a chemical compound

AcelRx initiated its first Phase 3 medical study for ARX-01.

AcelRx commences dosing in second ARX-01 Phase 3 clinical trial for acute post-operative pain AcelRx Pharmaceuticals, Inc. Related StoriesInner ear damage mind warnings from nerve cellsDiabetic retinopathy therapy innovations: an interview with Richard Kirk, CEO of PolyphotonixImmune submits Bertilimumab IND software to FDA for treatment of Bullous PemphigoidIn March 2012, AcelRx initiated its first Phase